Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.88USD
1:32am IST
Change (% chg)

$0.12 (+0.28%)
Prev Close
$42.76
Open
$42.73
Day's High
$42.90
Day's Low
$42.35
Volume
3,582,689
Avg. Vol
6,626,462
52-wk High
$46.46
52-wk Low
$35.74

Latest Key Developments (Source: Significant Developments)

Pfizer Inc Reports A Passive Stake Of 8.7% In Nextcure Inc As Of May 13, 2019
Thursday, 23 May 2019 

May 22 (Reuters) - NextCure Inc ::PFIZER INC REPORTS A PASSIVE STAKE OF 8.7% IN NEXTCURE INC AS OF MAY 13, 2019 - SEC FILING.  Full Article

Pfizer Confirms Initiation Of EU Review Of Tofacitinib With Interim Recommendations
Friday, 17 May 2019 

May 17 (Reuters) - Pfizer Inc ::PFIZER INC. - PFIZER CONFIRMS INITIATION OF EU REVIEW OF TOFACITINIB WITH INTERIM RECOMMENDATIONS.PFIZER INC - CONTINUES TO WORK WITH REGULATORY BODIES AND IS TAKING STEPS TO INFORM HEALTHCARE PROFESSIONALS IN EU/EEA ABOUT THIS INTERIM GUIDANCE.PFIZER INC - CONFIRMS THAT EMA ISSUED RECOMMENDATIONS LIMITING USE OF XELJANZ 10 MG TWICE DAILY IN SUBSET OF PATIENTS WITH ULCERATIVE COLITIS IN EU.PFIZER - RECOMMENDATIONS FROM EMA ARE TEMPORARY WHILE EMA'S COMMITTEE UNDERTAKES REVIEW OF ALL AVAILABLE EVIDENCE ON SAFETY, EFFICACY OF TOFACITINIB.PFIZER - REVIEW IS RESULT OF OBSERVATION OF INCREASED RISK OF PE WITH TOFACITINIB 10 MG TWICE DAILY IN ONGOING FDA POST-MARKETING REQUIREMENT STUDY.  Full Article

Pfizer's dermatitis treatment meets main goals of late-stage study
Wednesday, 15 May 2019 

May 15 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL ORAL JAK1 CANDIDATE, ABROCITINIB (PF-04965842), IN PATIENTS AGED 12 AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS.PFIZER- BY WEEK 12, PERCENT OF PATIENTS ACHIEVING CO-PRIMARY EFFICACY ENDPOINTS WITH EITHER DOSE WAS STATISTICALLY SIGNIFICANTLY HIGHER VERSUS PLACEBO .PFIZER- BY WEEK 12, PERCENT OF PATIENTS ACHIEVING EACH SECONDARY ENDPOINT WITH EITHER DOSE WAS STATISTICALLY SIGNIFICANTLY HIGHER VERSUS PLACEBO .PFIZER INC - STUDY ACHIEVES ALL CO-PRIMARY AND SECONDARY ENDPOINTS.PFIZER INC - RESULTS DEMONSTRATE RESPONSE TO TREATMENT FOR A STATISTICALLY SIGNIFICANT NUMBER OF PATIENTS.PFIZER INC - SAFETY RESULTS SHOW THAT BOTH DOSES OF ABROCITINIB WERE WELL-TOLERATED, AND THERE WERE NO UNEXPECTED SAFETY EVENTS.PFIZER - DISCONTINUATION RATES DUE TO AN ADVERSE EVENT WERE LOW IN EACH TREATMENT ARM (5.8% AND 5.8% IN 100MG AND 200MG) COMPARED TO PLACEBO (9.1%).  Full Article

Pfizer's Atopic Dermatitis Study Achieves All Co-Primary And Secondary Endpoints
Wednesday, 15 May 2019 

May 15 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL ORAL JAK1 CANDIDATE, ABROCITINIB (PF-04965842), IN PATIENTS AGED 12 AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS.PFIZER INC - STUDY ACHIEVES ALL CO-PRIMARY AND SECONDARY ENDPOINTS.PFIZER INC - TOP-LINE RESULTS SHOWED THAT BY WEEK 12 PERCENTAGE OF PATIENTS ACHIEVING EACH CO-PRIMARY EFFICACY ENDPOINT.PFIZER INC - SECONDARY ENDPOINT WITH EITHER DOSE OF ABROCITINIB WAS STATISTICALLY SIGNIFICANTLY HIGHER THAN PLACEBO.PFIZER INC - RESULTS DEMONSTRATE RESPONSE TO TREATMENT FOR A STATISTICALLY SIGNIFICANT NUMBER OF PATIENTS.PFIZER INC - SAFETY RESULTS SHOW BOTH DOSES OF ABROCITINIB WERE WELL-TOLERATED, AND THERE WERE NO UNEXPECTED SAFETY EVENTS.PFIZER INC - SAFETY RESULTS SHOW THAT BOTH DOSES OF ABROCITINIB WERE WELL-TOLERATED, AND THERE WERE NO UNEXPECTED SAFETY EVENTS.PFIZER - DISCONTINUATION RATES DUE TO AN ADVERSE EVENT WERE LOW IN EACH TREATMENT ARM (5.8% AND 5.8% IN 100MG AND 200MG) COMPARED TO PLACEBO (9.1%).  Full Article

Australian competition regulator Not To Oppose GSK's Proposed Acquisition Of Pfizer's Consumer Healthcare Business In Australia
Thursday, 9 May 2019 

May 9 (Reuters) - Australian Competition and Consumer Commission::WILL NOT OPPOSE GSK’S PROPOSED ACQUISITION OF PFIZER’S CONSUMER HEALTHCARE BUSINESS IN AUSTRALIA.ACCC CONSIDERS THAT TRANSACTION WILL NOT SUBSTANTIALLY LESSEN COMPETITION IN ANY MARKET IN AUSTRALIA.  Full Article

Pfizer Acquires Clinical-Stage Biotech Therachon
Wednesday, 8 May 2019 

May 8 (Reuters) - Pfizer Inc ::PFIZER ACQUIRES CLINICAL-STAGE BIOTECH THERACHON.PFIZER INC - ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE ALL SHARES OF THERACHON HOLDING AG.PFIZER - WILL ACQUIRE THERACHON FOR $340 MILLION UPFRONT WITH AN ADDITIONAL $470 MILLION IN ADDITIONAL PAYMENTS CONTINGENT ON ACHIEVEMENT OF MILESTONES.PFIZER INC - NO OTHER TERMS OF TRANSACTION WERE DISCLOSED..PFIZER - $470 MILLION IN ADDITIONAL PAYMENTS CONTINGENT ON ACHIEVEMENT OF MILESTONES IN DEVELOPMENT, COMMERCIALIZATION OF TREATMENT OF ACHONDROPLASIA.  Full Article

Pfizer gets U.S. approval for $225,000 a year heart drug
Monday, 6 May 2019 

May 6 (Reuters) - Pfizer Inc ::PFIZER SAYS FDA APPROVES VYNDAQEL AND VYNDAMAX FOR USE IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY.PFIZER SAYS FDA APPROVAL WAS BASED ON DATA FROM PIVOTAL PHASE 3 TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY CLINICAL TRIAL (ATTR-ACT).PFIZER SAYS PRICE FOR TAFAMIDIS IN THE U.S. WILL BE $225,000 PER YEAR.  Full Article

GlaxoSmithKline Posts Q1 Adj EPS 30.1 Pence
Wednesday, 1 May 2019 

May 1 (Reuters) - GlaxoSmithKline Plc ::Q1 ADJUSTED EPS ROSE 22 PERCENT TO 30.1 PENCE.Q1 SALES ROSE 6 PERCENT TO 7.7 BILLION STG.2019 GUIDANCE REAFFIRMED.QTRLY TOTAL EPS 16.8P.19P DIVIDEND DECLARED FOR QUARTER; CONTINUE TO EXPECT 80P FOR FULL YEAR 2019.QTRLY TOTAL HIV SALES 1.1 BILLION STG, +7 PCT AER, +4 PCT CER, INCLUDING JULUCA SALES OF 70 MILLION STG.2019 GUIDANCE REFLECTS RECENT APPROVAL OF SUBSTITUTABLE GENERIC COMPETITOR TO ADVAIR IN US AND EXPECTED IMPACT OF TESARO ACQUISITION.QTRLY PHARMACEUTICALS TURNOVER 4,158 MILLION POUNDS VERSUS 4,009 MILLION POUNDS REPORTED A YEAR EARLIER.2019 GUIDANCE ASSUMES THAT PROPOSED CONSUMER HEALTHCARE NUTRITION DISPOSAL CLOSES BY END OF 2019.QTRLY VACCINES TURNOVER 1,522 MILLION POUNDS VERSUS 1,238 MILLION POUNDS REPORTED A YEAR EARLIER.2019 GUIDANCE ALSO ASSUMES PROPOSED CONSUMER HEALTHCARE JOINT VENTURE WITH PFIZER CLOSES DURING H2 2019.DECISION HAS BEEN MADE TO TERMINATE CLINICAL DEVELOPMENT OF STREP PNEUMONIA (NEXT GENERATION) CANDIDATE VACCINE.QTRLY CONSUMER HEALTHCARE TURNOVER 1,981 MILLION POUNDS VERSUS 1,975 MILLION POUNDS REPORTED A YEAR EARLIER.DECISION HAS BEEN MADE TO NO LONGER PURSUE CLINICAL DEVELOPMENT OF CANDIDATE UNIVERSAL FLU VACCINE."REMAINS COMMITTED TO FURTHER RESEARCH IN FLU INCLUDING PURSUING OTHER APPROACHES".IF EXCHANGE RATES HOLD AT CLOSING RATES ON 31 MARCH FOR REST OF 2019, ESTIMATED NEGATIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE AROUND 1 PCT.  Full Article

Pfizer Says Business Development Focus Will Be On Earlier To Mid-Stage Opportunities
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Pfizer Inc ::PFIZER CEO SAYS IBRANCE GROWTH STORY NOW PREDOMINANTLY IN INTERNATIONAL MARKETS, SAYS CANCER DRUG SAW STRONG UPTAKE IN DEVELOPED EUROPE, JAPAN AND CERTAIN EMERGING MARKETS - CONF. CALL.PFIZER SAYS SALES OF PNEUMONIA VACCINE PREVNAR HELPED BY GROWTH IN EMERGING MARKETS AND INCREASED VOLUME ASSOCIATED WITH GOVERNMENT PROCESSES - CONF. CALL.PFIZER SAYS CONSUMER HEALTHCARE REVENUE HURT BY MILDER THAN EXPECTED COLD AND COUGH SEASON IN UNITED STATES - CONF. CALL.PFIZER SAYS BUSINESS DEVELOPMENT FOCUS WILL BE ON EARLIER TO MID-STAGE OPPORTUNITIES - CONF. CALL.PFIZER WILL LOOK AT BOLT-ON DEALS OF "A FEW BILLION DOLLARS" TO COMPLEMENT PIPELINE - CONF. CALL.PFIZER SAYS GENE THERAPY IS AN AREA OF SIGNIFICANT FOCUS FOR CO - CONF. CALL.PFIZER EXPECTS UPJOHN BUSINES TO DECLINE THIS YEAR DUE TO LYRICA LOSS OF PATENT- CONF. CALL.  Full Article

Pfizer Inc - Qtrly Worldwide Total Lyrica Revenue $1,186 Million Versus $1,213 Million
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Pfizer Inc ::PFIZER INC - QTRLY WORLDWIDE TOTAL LYRICA REVENUE $1,186 MILLION VERSUS $1,213 MILLION.PFIZER INC - QTRLY WORLDWIDE PREVNAR FAMILY REVENUE $1,486 MILLION VERSUS $1,380 MILLION.PFIZER INC - QTRLY WORLDWIDE IBRANCE REVENUE $1,133 MILLION VERSUS $933 MILLION.  Full Article

Photo

Faith in the Fed nudges Wall Street higher

Wall Street edged higher on Monday, supported by Facebook, Amazon and Apple, as investors awaited a key Federal Reserve meeting that is expected to lay the groundwork for an interest rate cut later this year. | Video